Member Info for ceejay101

Thanks leas.

I've had a look at the Biondvax company presentation June 2018.

Page 13 mentions new strains that are protected for up to 5 years. Seek/Hvivo and other competitors are called out on page 16.

Potential j/v companies listed on page 18.

Biondvax are already heading into P3 and market cap of $42m.

I agree that there is positive news coming here, hopefully as soon as next week in terms of the underlying data. I'm trying to understand what is the differentiator between Hvivo and Biondvax

I've looked up an can see that a company called BiondVax has been working on their own universal flu treatment. Can anyone tell me how Hvivo stacks up against them?

FYI - i am invested in HVivo

i think we are in from the links that matrix posted earlier Top Small Caps... https://uk.webfg.com/index/FTSE_Small_Cap/market-capitalization/desc Bottom FTSE 250 https://uk.webfg.com/index/FTSE_250/market-capitalization/asc

from looking in the past i think companies tend to have a gradual movement over a two month period when moved as part of a reshuffle. The big funds will be weighted towards the FTSE100. We might see some buying but not huge amounts. it will be interesting to see where ocado goes next quarter. As for PMO we are v. price sensitive to POO and i suspect entrance into FTSE250 will make that even more pronounced.

PMO is in from what i have checked https://uk.webfg.com/index/FTSE_All-Share/market-capitalization/asc Evening standard also has PMO as in